Biovie (BIVI) Total Non-Current Liabilities (2017 - 2024)
Biovie (BIVI) posted Total Non-Current Liabilities of $1.8 million for Q4 2024, down 75.39% sequentially from $7.2 million in Q3 2024, and down 87.39% YoY from $14.0 million in Q1 2024.
Biovie (BIVI) Total Non-Current Liabilities (2017 - 2024) Analysis & Trends
Biovie has reported Total Non-Current Liabilities for 8 years, with the latest figure at $1.8 million in Q4 2024.
- Quarterly Total Non-Current Liabilities fell 87.39% year-over-year to $1.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.8 million (down 87.39% YoY) and the FY2024 annual result came in at $9.7 million, down 48.6% from the prior year.
- Total Non-Current Liabilities slipped to $1.8 million in Q4 2024 per BIVI's latest filing, from $7.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $21.5 million in Q1 2023 and troughed at -$571473.0 in Q1 2020.
- A 5-year average of $11.9 million and a median of $14.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 1205.95% in 2022, then slumped 87.39% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $7.2 million in 2020, then soared by 103.46% to $14.6 million in 2021, then surged by 32.15% to $19.3 million in 2022, then dropped by 27.43% to $14.0 million in 2023, then plunged by 87.39% to $1.8 million in 2024.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.8 million, $7.2 million, and $9.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.76 Mn |
| Sep 30, 2024 | 7.17 Mn |
| Jun 30, 2024 | 9.70 Mn |
| Mar 31, 2024 | 12.80 Mn |
| Dec 31, 2023 | 13.99 Mn |
| Sep 30, 2023 | 15.72 Mn |
| Jun 30, 2023 | 18.87 Mn |
| Mar 31, 2023 | 21.51 Mn |
| Dec 31, 2022 | 19.28 Mn |
| Sep 30, 2022 | 16.46 Mn |
| Jun 30, 2022 | 16.26 Mn |
| Mar 31, 2022 | 14.76 Mn |
| Dec 31, 2021 | 14.59 Mn |
| Sep 30, 2021 | 1.26 Mn |
| Jun 30, 2020 | 7.17 Mn |
| Mar 31, 2020 | -571,473.00 |
| Dec 31, 2019 | -334,456.00 |
| Sep 30, 2019 | 8.80 Mn |
| Jun 30, 2018 | 825,918.00 |
| Mar 31, 2018 | 575,917.00 |